The NTIS website and supporting ordering systems are undergoing a major upgrade from 8PM on September 25th through approximately October 6. During that time, much of the functionality, including subscription and product ordering, shipping, etc., will not be available. You may call NTIS at 1-800-553-6847 or (703) 605-6000 to place an order but you should expect delayed shipment. Please do NOT include credit card numbers in any email you might send NTIS.
Documents in the NTIS Technical Reports collection are the results of federally funded research. They are directly submitted to or collected by NTIS from Federal agencies for permanent accessibility to industry, academia and the public.  Before purchasing from NTIS, you may want to check for free access from (1) the issuing organization's website; (2) the U.S. Government Printing Office's Federal Digital System website http://www.gpo.gov/fdsys; (3) the federal government Internet portal USA.gov; or (4) a web search conducted using a commercial search engine such as http://www.google.com.
Accession Number ADA583591
Title TRNAs as Therapeutic Agents of Breast Cancer.
Publication Date Jul 2013
Media Count 14p
Personal Author D. Zhou M. Rosner Q. Dai R. Geslain T. Pan
Abstract Transfer RNAs (tRNA) are small non-coding RNAs that read the genetic codes in protein synthesis. It is essential for the proliferation, fitness and adaptation of the cell that each tRNA is aminoacylated (charged) with its designated amino acid. The utilization of mischarged tRNAs (i.e. tRNAs with incompatibly charged amino acid and decoding capacity) leads to the synthesis of mutated proteins that can fold incorrectly. Accumulation of misfolded proteins in the cell activates an integrated cellular mechanism, the Unfolded Protein Response which dictates cell fate in response to the amount of misfolded proteins. High accumulation of misfolded proteins derived from the cellular presence of mischarged tRNAs can therefore induce apoptosis of the cell. We aim to engineer tRNAs that are always mischarged in a human cell and study their effects on breast tumor cell physiology and cell death. Protein demand in rapidly proliferating cells is extremely high and small defects during cellular protein synthesis caused by the presence of such tRNAs can have a strong impact on both tumor invasiveness and survival. Ultimately, we aim to demonstrate that these mischarged tRNAs can be developed as a novel class of RNA-based agents to treat breast tumors.
Keywords Amino acids
Apoptosis
Biosynthesis
Breast cancer
Chemotherapeutic agents
Death
Therapy


 
Source Agency Non Paid ADAS
NTIS Subject Category 57A - Anatomy
57S - Physiology
57E - Clinical Medicine
Corporate Author Chicago Univ., IL.
Document Type Technical report
Title Note Final rept. 1 Jul 2012-30 Jun 2013.
NTIS Issue Number 1401
Contract Number W81XWH-10-1-0014

Science and Technology Highlights

See a sampling of the latest scientific, technical and engineering information from NTIS in the NTIS Technical Reports Newsletter

Acrobat Reader Mobile    Acrobat Reader